Guillain-Barré syndrome (GBS) Market to Exhibit Substantial Growth Rate During the Forecast Period (2023-2032) - DelveInsight | Key Companies - Alexion Pharmaceuticals, Annexon, Argenx, Hansa Biopharma, Bioasis Technologies, Immunic

The Guillain-Barré syndrome (GBS) market is witnessing advancements in diagnostic techniques and treatment options, catering to the complex needs of patients. Emerging therapies targeting the underlying autoimmune response show promise in mitigating symptoms and improving outcomes. Additionally, increased awareness among healthcare professionals and the public is fostering early detection and intervention, contributing to a more proactive approach in managing GBS.

DelveInsight's "Guillain-Barré syndrome Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Guillain-Barré syndrome Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Guillain-Barré syndrome therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Guillain-Barré syndrome treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Guillain-Barré syndrome: An Overview
Guillain-Barré syndrome (GBS) can be described as a collection of clinical syndromes that manifests as acute inflammatory polyradiculoneuropathy with resultant weakness and diminished reflexes. With poliomyelitis under control in developed countries, GBS is now the most important cause of acute flaccid paralysis. The etiology of GBS is not entirely understood but is believed to be due to autoimmune causes, where the majority of cases are triggered by infection-stimulating anti-ganglioside antibody production.

Unexplained sensations often occur first, such as tingling in the feet or hands or even pain (especially in children), often starting in the legs or back. Children will also show symptoms of difficulty in walking and may refuse to walk. These sensations tend to disappear before the major, longer-term symptoms appear.

Most people reach the greatest stage of weakness within the first two weeks after symptoms appear; by the third week, 90% of affected individuals are at their weakest. GBS is considered a clinical diagnosis; therefore, a diagnosis can be made with confidence at the bedside in most cases. For atypical cases or unusual subtypes, ancillary testing can be useful.

Guillain-Barré syndrome Market Key Facts
• According to the National Organization of Rare Disorders (NORD), GBS affects about one or two people each year in every 100,000 population. Its exact cause is unknown. About half the disease population has a gastrointestinal or respiratory infection a few days before the onset.
• According to the World Health Organization (n.d.), people of all ages can be affected by GBS, but it is more common in adults and males. Most people recover fully from even the most severe cases of GBS. Also, although severe cases of GBS are rare, it can result in near-total paralysis.
• As per Kuwabara (2004), GBS occurs throughout the world with a median annual incidence of 1.3 cases per population of 100,000, with men being more frequently affected than women.

Get a Detailed Overview of the Evolving Guillain-Barré syndrome Market Trends @
https://www.delveinsight.com/report-store/guillain-barre-syndrome-gbs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Guillain-Barré syndrome Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Guillain-Barré syndrome therapies in the market. It also provides a detailed assessment of the Guillain-Barré syndrome market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete details of the market trend for each marketed Guillain-Barré syndrome drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How the Guillain-Barré syndrome Market Will Grow by 2032 @
https://www.delveinsight.com/report-store/guillain-barre-syndrome-gbs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Guillain-Barré syndrome Epidemiology
The epidemiology section covers detailed insights into the historical, and current Guillain-Barré syndrome patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Guillain-Barré syndrome Epidemiology Segmented as -
• Total Incident Cases of Guillain-Barré syndrome
• Gender-specific Incident Cases of Guillain-Barré syndrome
• Age-specific Incident Cases of Guillain-Barré syndrome
• Treatable Cases of Guillain-Barré syndrome

Get Key Insights Into the Evolving Guillain-Barré syndrome Epidemiology Trends @
https://www.delveinsight.com/report-store/guillain-barre-syndrome-gbs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Guillain-Barré syndrome Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Guillain-Barré syndrome market or expected to be launched during the study period. The analysis covers the market share by Guillain-Barré syndrome drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Guillain-Barré syndrome Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities in the Guillain-Barré syndrome Market @
https://www.delveinsight.com/sample-request/guillain-barre-syndrome-gbs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Guillain-Barré syndrome Therapeutics Assessment
Treatment of GBS is subdivided into (a) the management of severely paralyzed patients with intensive care and ventilatory support and (b) specific immunomodulating treatments that shorten the progressive course of GBS, presumably by limiting nerve damage. High-dose intravenous immunoglobulin (IVIg) therapy and plasma exchange aid in more rapid resolution of the disease. The predominant mechanisms by which IVIg therapy exerts its action appear to be a combined effect of complement inactivation, neutralization of idiotypic antibodies, cytokine inhibition, and saturation of FC receptors on macrophages. Corticosteroids alone do not alter the outcome of GBS.

Two treatments accelerate recovery from GBS, plasma exchange (PE, also called plasmapheresis) and intravenous immune globulin (IVIg). PE connects one vein via a thin plastic tube to a machine that separates the plasma (the liquid portion of the blood) from the red blood cells and returns the red blood cells with a plasma substitute via another vein. It removes harmful substances, especially the antibodies that cause GBS.

To further improve the treatment scenario, there are approx. 8+ key companies developing therapies for Guillain-Barré syndrome. Currently, Alexion Pharmaceuticals is leading the therapeutics market with its Guillain-Barré syndrome drug candidates in the most advanced stage of clinical development.

Leading Companies in the Guillain-Barré syndrome Therapeutics Market Include
• Alexion Pharmaceuticals
• Annexon
• Argenx
• Hansa Biopharma
• Bioasis Technologies
• Immunic
And Many Others

Emerging and Marketed Guillain-Barré syndrome Therapies Covered in the Report Include
• Eculizumab: Alexion Pharmaceuticals
• Efgartigimod Alfa-Fcab: argenx
• CRES-101: Bioasis Technologies, Inc.
• Imlifidase: Hansa Biopharma AB
• IMU 935: Immunic
And Many More

Learn More About the Emerging Therapies and key Companies in the Guillain-Barré syndrome Therapeutics Market @
https://www.delveinsight.com/sample-request/guillain-barre-syndrome-gbs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Guillain-Barré syndrome Competitive Intelligence Analysis
4. Guillain-Barré syndrome Market Overview at a Glance
5. Guillain-Barré syndrome Background and Overview
6. Guillain-Barré syndrome Patient Journey
7. Guillain-Barré syndrome Epidemiology and Patient Population
8. Guillain-Barré syndrome Treatment Algorithm, Current Treatment, and Medical Practices
9. Guillain-Barré syndrome Unmet Needs
10. Key Endpoints of Guillain-Barré syndrome Treatment
11. Guillain-Barré syndrome Marketed Products
12. Guillain-Barré syndrome Emerging Therapies
13. Guillain-Barré syndrome Seven Major Market Analysis
14. Attribute Analysis
15. Guillain-Barré syndrome Market Outlook (7 major markets)
16. Guillain-Barré syndrome Access and Reimbursement Overview
17. KOL Views on the Guillain-Barré syndrome Market.
18. Guillain-Barré syndrome Market Drivers
19. Guillain-Barré syndrome Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/guillain-barre-syndrome-gbs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.